Everspin Technologies MRAM Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF

Heartflow, Inc. Common StockHTFL

$15.41M-25.5%

PhotronicsPLAB

$3.9M+43.5%

KEE

Keel Infrastructure Corp. Common StockKEEL

$2.19M-50.8%

Tarsus Pharmaceuticals, Inc.TARS

$7.96M-63.4%

Lantheus HoldingsLNTH

$6.19M-79.2%

Frequency ElectronicsFEIM

$2.25M+104%

Other financials

Income statement

See full

Revenue$14.9M+13.2%

Gross profit$7.8M+16.1%

Operating income-$2.7M-40.6%

Net income-$296.0K+74.6%

EPS (diluted)-$0.01+80.0%

Balance sheet

See full

Cash & equivalents$40.5M-3.9%

Total debt$1.3M-56.8%

Total equity$70.2M+11.4%

Total assets$83.2M+3.7%

Cash flow

See full

Operating cash flow$570.0K-60.4%

CapEx$4.4M+377%

Free cash flow-$3.8M-818%

Valuation

See full

Market cap$512.1M+279%

Enterprise value$472.95M+392%

P/S9×+6.2×

Profitability

See full

Gross margin51.5%+1.2pp

Operating margin-12.8%-2.6pp

Net margin-1.1%-3.9pp

FCF margin11.5%+4.7pp

Returns & leverage

See full

Return on equity-0.9%-3.7pp

Debt / equity0×0.0×

Current ratio5.8×+0.5×

Where this comes from

Reported directly by Everspin Technologies in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.

The official record: Everspin Technologies’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Everspin Technologies's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Everspin Technologies's indefinite-lived research and development assets?: Everspin Technologies (MRAM) reported indefinite-lived research and development assets of $4.37M in Q4 2025.
What does indefinite-lived research and development assets mean?: The carrying value of acquired in-process research and development projects that have not yet reached technological feasibility. These assets are not amortized but are subject to periodic impairment testing, reflecting the company's investment in future product innovation.